Rapid replacement of bla KPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Ping Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Klebsiella Infections, Ceftazidime, Azabicyclo Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, Clinical Key Program of Peking University Third Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Hypervirulent ceftazidime/avibactam (CAZ/AVI)-resistant Klebsiella pneumoniae (Kp) has emerged; however, its dynamic within-host evolution and competitive features are uncharacterized. This study aimed to clarify the systematic microevolution characteristics of the rapid transformation of blaKPC variants during long-term infection.
Methods
Thirty-nine Kp strains were isolated from a single patient with severe recurrent osteomyelitis during a 2-year period. Whole-genome sequencing and in vitro evolution assay was performed. Microbiological characteristics were examined through antimicrobial susceptibility testing, plasmid stability, growth curve, in vitro competition and Galleria mellonella larvae lethality assays.
Results
Among all the clinical Kp isolates, 37 were carbapenem-resistant Kp (CRKP), including 25 CAZ-/AVI-resistant Kp. All isolates belonged to the ST11-K47. During in vivo evolution, the blaKPC variant and its amplification emerged. Twenty-four isolates (24/39, 61.5%) harboured a novel blaKPC variant, blaKPC-144. All five Kp isolates carried blaKPC-2 in 2021. Surprisingly, 24 blaKPC-144-harbouring isolates (70.6%, 24/34) and 10 blaKPC-2-harboring isolates were identified in 2023, indicating rapid changing of blaKPC. Kp4 carried two copies of blaKPC-2, and Kp10-1 exhibited a 1.94-fold increase in the blaKPC-144 copy number. Similarly, in vitro, the blaKPC copy number increased upon exposure to low CAZ/AVI concentrations. However, at higher concentrations (4/1 mg/L), the blaKPC copy number increased significantly, and blaKPC mutations emerged simultaneously. The competition assay indicated that the blaKPC-144-harboring isolates exhibited a superior competitive capacity.
Conclusions
The blaKPC amplification and mutation emerged simultaneously or sequentially during in vivo and in vitro evolution. Kp isolates harbouring blaKPC-144, conferring resistance to CAZ/AVI, exhibited a competitive advantage, promoting the rapid replacement of blaKPC-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
- Department of Infectious Diseases, Peking University Third Hospital, Beijing, China.
- Center of Infectious Disease, Peking University Third Hospital, Beijing, China.
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
- Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
- Department of Orthopaedics, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Chao Liu
Förderung
- National Key R&D Program of China
- Clinical Key Program of Peking University Third Hospital
- National Natural Science Foundation of China
- Peking University Clinical Scientist Training Program
Zitieren
APA
Yang, P., Liu, C., Zheng, J., Yi, J., Wu, Z., Tian, Y., Du, P., Lu, M., & Shen, N. (2025). Rapid replacement of bla KPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf337
Vancouver
Yang P, Liu C, Zheng J, Yi J, Wu Z, Tian Y, et al. Rapid replacement of bla KPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf337
BibTeX
@article{Yang2025,
author = {Yang, Ping and Liu, Chao and Zheng, Jiajia and Yi, Juan and Wu, Zhenchao and Tian, Yun and Du, Pengcheng and Lu, Ming and Shen, Ning},
title = {Rapid replacement of bla KPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf337}
}
EUVIMED